Boston Scientific Pops on Positive Review of Asthma Treatment Device

Jacob Harper |

On Sept 5 the Journal of Allergy and Clinical Immunology released data that showed the Alair Bronchial Thermoplasty (BT) System, an asthma treatment device manufactured by Boston Scientific Corporation (BSX) ,  is “safe and effective,” concluding a five-year study of the device. Boston Scientific’s stock shot up on the positive review, adding to an already triumphant year for the once-troubled healthcare company.

The journal findings concerning the BT System follow a series of successes of continual successes for the company’s products in 2013, even as analysts have remained skeptical of the company. In April, Credit Suisse downgraded Boston despite a strong first quarter. In May, Boston’s stock jumped 11 percent on a positive four-year follow up on their Watchman Left Atrial Appendage (LAA) closure device.

Then in July Citigroup (C) downgraded the stock as well. Following this downgrade, on July 25 Boston issued their second quarter 2013 earnings report crushing expectations.The company was spurred on by robust sales of both older devices and surprising successes in their neuromodulation devices and sending the stock soaring once more.  

Boston is still recovering from the disastrous $27.2 billion purchase of device maker Guidant in 2006. The move turned out to be a major blow to the company, forcing them to issue a major write-down amid lawsuits and recalls associated iwth Guidant products. Boston had already lost half its value at that point, and the slide continued. Since 2004, Boston has lost three-quarters of their market cap.

After languishing in 2011 and 2012, the company is rebounding in 2013. But sespite being the sixth-best performing stock in the S&P 500 this year, and the string of sucesses for its new devices, analysts are still wary of Boston. Of 18 analysts polled by NASDAQ, 14 have a “hold” rating on the stock, with four assigning a “strong buy.”

However, that trend may be finally reversing. Barclays Capital reiterated their “overweight” rating on the stock on Aug. 14, and has a price target of $12 a share. On Sept 4 Credit Suisse raised their price target on Boston from $11 a share to $12.

Natick, Mass.-headquartered Boston Scientific was up 6.68 percent on the day to hit $11.66 a share. They are up a whopping 85.57 percent on the year.

(image of courtesy of Wikimedia Commons)

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
C Citigroup Inc. 59.06 1.14 1.97 30,517,614
BSX Boston Scientific Corporation 20.61 -0.20 -0.96 11,443,188
PARXF Parex Resources Inc 12.82 -0.51 -3.81 500

Comments

Emerging Growth

CMX Gold & Silver Corp.

CMX Gold & Silver Corp is an exploration stage company. The Company is engaged in the acquisition, exploration and development of silver and copper/gold properties in the USA.

Private Markets

Pinterest

Pinterest is a visual discovery and planning tool. Users ("Pinners") use the site and apps to get ideas for their future, such as recipes, places to travel, and products to…

Spotify

Spotify is a online music service offering providing digital content from a range of record labels and artists. Users can browse through the interface by artist, album, genre, playlist, record…